Drug Profile
BXCL 502
Alternative Names: BXCL 502Latest Information Update: 15 Mar 2022
Price :
$50
*
At a glance
- Originator Inveni
- Developer BioXcel Therapeutics
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Agitation
- Discontinued Neurodegenerative disorders
Most Recent Events
- 15 Mar 2022 Discontinued - Phase-I/II for Neurodegenerative disorders (unspecified route) before March 2022 (BioXcel Therapeutics' pipeline, March 2022)
- 10 Mar 2022 Preclinical trials in Agitation in USA (unspecified route) before March 2022
- 16 Mar 2021 No development reported - Phase-I/II for Neurodegenerative disorders (unspecified route)